We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the Soluble urokinase plasminogen activator receptor serum levels in patients with Parkinson's disease.
- Authors
Gurol Ciftci, Gonul; Karakece, Engin; Hakki Ciftci, Ihsan; Kotan, Dilcan
- Abstract
Parkinson's disease (PD) is the most widespread neurological disorders characterized by degeneration of cognitive and/or motor functions. Numerous evidences have established the role of neuroinflammation in the PD pathology. Soluble urokinase plasminogen activator receptor (suPAR) is a highly sensitive marker that reflects increased inflammation and is positively correlated with pro inflammatory biomarkers. In this pilot study, suPAR serum levels were investigated in patients with PD. Twenty patients with PD were recruited from outpatient clinics of Neurology department. Diagnosis of PD was based on United Kingdom PD Society Brain Bank Diagnostic Criteria. Secondary causes or other neurodegenerative diseases were excluded. The serum suPAR concentration was quantified by enzyme-linked immunosorbent assays (ELISA). This is an experimental study. In this study, in vitro samples were investigated; any samples were not taken from patient. The patients with PD were done with two sections according to disease duration, early stage of PD (ESPD, n=10) and late stage of PD (LSPD, n=10). Relating to disease duration, suPAR levels were found significantly different. In LSPD group was found high suPAR level (2.7±1.1 ng/mL) than ESPD group (1.9±0.6 ng/mL) (p=0.028). The suPAR serum levels did show statistical significant differences in patient conditions in terms of clinical features such as dyskinesia, unified PD rating scale (UPDRS), Hohn-Yahr Staging Scale (HY) and MMSE status. The uPAR is expressed on a number of different cells including monocytes, macrophages and neutrophils.[Serum levels of suPAR have been shown to be a possible indicator in patients with various diseases, such as cancer, autoimmune diseases, tuberculosis and sepsis. Furthermore, high levels of suPAR are accused with increased risk of mortality and ref lect disease severity. The use of suPAR may be recommended for differentiation of disease severity in patients with PD. But prospective studies should be planed about suPAR end-point levels for ESPD and LSPD.
- Subjects
UROKINASE; PARKINSON'S disease; NEUROLOGICAL disorders; ENZYME-linked immunosorbent assay; DYSKINESIAS
- Publication
Turkish Journal of Immunology, 2016, Vol 4, p53
- ISSN
1301-109X
- Publication type
Article